Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes.

ABSTRACT: The central paradigm of novel therapeutic approaches in cancer therapy is identifying and targeting molecular biomarkers. One such target is the nuclear DNA repair enzyme Poly-(ADP ribose) polymerase 1 (PARP1). Sensitivity to PARP inhibition in certain cancers such as gBRCAmut breast and ovarian cancers has led to its exploitation as a target. The overexpression of PARP1 in several types of cancer further evoked interest in its use as an imaging target. While PARP1-targeted inhibitors have fast developed and approved in this past decade, determination of PARP1 expression might help to predict the response to PARP inhibitor treatment. This has the potential of improving prognosis and moving towards tailored therapy options and/or dosages. This review summarizes the recent pre-clinical advan

SUBMITTER: Ambur Sankaranarayanan R 

PROVIDER: S-EPMC7408801 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature